NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Tango Therapeutics, Inc. (TNGX) Stock Analysis

Tango Therapeutics, Inc. (TNGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TNGX

$22.52

−$0.24 (−1.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TNGX with… →

TNGX Key Statistics

As of Sep 4, 2026
Trading
Open
$22.48
Previous Close
$22.76
Day's Range
22.29–22.94
52-Week Range
6.25–34.39
Volume
1.46M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.12
Valuation
Market Cap
$3.80B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
70.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.84
Financials (FY)
Revenue (FY)
$62.38M+48.29%
Net Income (FY)
−$101.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
−229.92%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
168.61M
1-Year Return
+229.72%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
3.72M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TNGX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+154.18%
2025+186.73%
2024−68.79%
2023+36.55%
2022−33.73%
2021−4.37%
2020 (partial year)+11.83%

As of September 4, 2026.

TNGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$62.38M−$101.59M−162.9%
2024$42.07M−$130.30M−309.7%
2023$36.53M−$101.74M−278.5%
2022$24.86M−$108.18M−435.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$62.38M—−$111.29M−$101.59M−162.9%
2024$42.07M—−$145.60M−$130.30M−309.7%
2023$36.53M—−$114.17M−$101.74M−278.5%
2022$24.86M—−$111.07M−$108.18M−435.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TNGX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTNGXBiotechnology medianvs median
P/S ratio70.5615.264.6x the median
Profit margin−229.92%0.00%229.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tango Therapeutics, Inc. (TNGX) at $3.80B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 137.

The 52-week range on file runs from $6.25 to $34.39. TNGX last closed at $22.52 on September 4, 2026. That is −$0.24 (−1.05%) against the previous close. The latest close sits 260.32% above that 52-week low.

Financial Health

In fiscal 2025, Tango Therapeutics, Inc. reported revenue of $62.38M. That is +48.29% against the prior fiscal year, when revenue was $42.07M. The same year closed with a net loss of $101.59M. The reported profit margin is −229.92%. That is 229.9 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.84.

Across the 4 fiscal years on file, revenue moves from $24.86M in 2022 to $62.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 70.56. On price-to-sales that is 4.6 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +229.72%. Measured over 5 years, that is +11.74% a year compounded. Beta against the wider market is reported at 1.12. Annualized volatility over the trailing 6 years is 95.08%.

Growth & Income

The record shows no dividend for TNGX.

So far in 2026 the price is +154.18%. Across the complete calendar years on file, 2025 returned +186.73% and 2024 returned −68.79%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Tango Therapeutics, Inc. (TNGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tango Therapeutics, Inc. TNGX $3.80B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Tango Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Visit website →